Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation

Evaluation of the Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation

A prospective cohort study to evaluate the response to COVID-19 vaccine in liver transplantation patients.

fifty living donor liver transplantation recipients during maintenance immunosuppression phase will be vaccinated against COVID-19 followed by assessment of immune response to the vaccine and further investigation of correlation of immune response to genetic polymorphisms of HLA DRB1(rs2647087) gene and IL-18 (rs187238 and rs917997) gene.

Inclusion Criteria:

• Age>18
• At least 3 month post transplantation

Exclusion Criteria:

• pediatric recipients
• Active covid infection at the time of the study
• Pregnancy
• Allergy to any ingredients included in the vaccine
• Lactation in first six month of delivery
• Active Acute cellular rejection proven by liver biopsy
• Acute Febrile state with either leucopenia or leucocytosis
• High dose of corticosteroid at study timing (pulse methyl prednisolone)